TW201302756A - Pharmaceutical composition of Temozolomide comprising Vitamin C or its derivatives and preparation method thereof - Google Patents

Abstract

The present invention relates to pharmaceutical compositions comprising Temozolomide or a pharmaceutically acceptable salt thereof. Said compositions comprise Temozolomide or its pharmaceutically acceptable salt and Vitamin C and/or Vitamin C derivatives. Vitamin C or Vitamin C derivatives increase the dissolution of said Temozolomide.

Description

Temozolomide pharmaceutical composition containing vitamin C or its derivative and preparation method thereof

The present invention relates to a stable temozolomide pharmaceutical composition comprising the antitumor drug temozolomide or a pharmaceutically acceptable salt thereof, vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof.

Temozolomide chemical name: 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazin-8-decylamine, An alkylating agent having an antitumor activity of imidazotetrazine, developed by Schering & Plough. Temozolomide is indicated for newly diagnosed glioblastoma multiforme, initially combined with radiotherapy, followed by adjuvant therapy; temozolomide is also indicated for glioblastoma or anaplastic stellate cells that recur or progress after conventional therapy tumor. In 1998, temozolomide capsules were first marketed in the European Union, and subsequently listed in the US in 1999 by the US FDA. Temozolomide is currently the first line of treatment for malignant brain tumors and has been evaluated by the United States and the European medical community as the "gold standard" for the treatment of malignant brain tumors.

At present, the domestic formulation of temozolomide is a hard capsule. The oral preparation is convenient to use, and can be completely absorbed after oral administration. The bioavailability is as high as 98%. The main side effects are nausea, vomiting, fatigue, constipation and mild myelosuppression, among which severe nausea, Side effects such as vomiting are common. This often causes fluctuations in drug absorption, which affects bioavailability. Some patients have nausea and vomiting reactions that are too severe to be administered orally, and many patients in the clinic have difficulty swallowing and cannot be administered orally. There is an urgent need for temozolomide preparations that can be administered intravenously. However, temozolomide is stable at pH<7, and easily decomposes at pH>7. Temozolomide is a prodrug and is easily degraded into an active product in aqueous solution. Preparation of a conventional intravenous solution does not guarantee long-term stability.

To achieve parenteral administration of temozolomide, a temozolomide formulation administered in a micronized suspension is disclosed in U.S. Patent No. 6,251,886, however, suspension formulations are not preferred and can cause vascular occlusion. Considering the unstable nature of temozolomide in aqueous solution, it is prepared by freeze-drying and solidification to prepare a sterile lyophilized powder, which is reconstituted with an aqueous diluent for injection before use to obtain a temozolomide injection which can be administered parenterally. It will be a good strategy.

In addition, U.S. Patent No. 6,987,108 discloses a lyophilized powder injection of temozolomide for intravenous administration of temozolomide. However, the concentration of temozolomide before lyophilization was 2.5 mg/mL, and the concentration was too low, which caused the volume to be too large before lyophilization, which was not conducive to the preparation of the preparation. Therefore, there is a need to develop a technique and a preparation thereof which are capable of ensuring the parenteral administration of temozolomide, which is stable and capable of increasing the solubility of temozolomide.

SUMMARY OF THE INVENTION A primary object of the present invention is to provide a stable temozolomide pharmaceutical composition in which temozolomide is well soluble and a method of preparing the composition. The inventors discovered by research that vitamin C and its derivatives have an effect of improving the solubility of temozolomide.

The present invention provides a pharmaceutical composition comprising temozolomide or a pharmaceutically acceptable salt thereof, and at least one vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof. Vitamin C or derivatives thereof useful in the present invention include various ester or structural modifications of vitamin C, such as phosphates, palmitates, glucosides, and the like, and pharmaceutically acceptable salts of vitamin C include various metal salts such as VC sodium, VC calcium, VC phosphate sodium, and the like.

Vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof which is preferably used in the present invention is vitamin C.

Further, the pharmaceutical composition of the present invention further comprises at least one aqueous diluent.

The pharmaceutical composition of the present invention is preferably an injectable parenteral pharmaceutical preparation, and more preferably the composition is in the form of a lyophilized powder.

The person skilled in the art can recognize that the addition of the vitamin C or the derivative thereof of the present invention has an effect of improving the solubility of temozolomide, and the amount thereof is not particularly limited. In a preferred pharmaceutical composition, temozolomide or a pharmaceutically acceptable salt thereof, based on temozolomide, vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof, in terms of vitamin C, the weight ratio of vitamin C to temozolomide is 0.5 to 10:1; preferably 1 to 5:1 by weight; more preferably 2:1 by weight.

In the pharmaceutical composition of the present invention, the content of vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof is from 10% by weight to 80% by weight, preferably from 25% by weight to 65% by weight based on the total weight of the pharmaceutical composition; The total weight of the pharmaceutical composition is temozolomide or a pharmaceutically acceptable salt thereof in an amount of from 5 to 60% by weight, preferably from 10 to 30% by weight.

The pharmaceutical composition of the present invention may comprise one or more of an excipient, a wetting agent, a pH adjuster or a buffer, preferably a mannitol; the wetting agent is a polysorbate, preferably Polysorbate 80; the pH adjuster is hydrochloric acid; the buffer is selected from the group consisting of sodium citrate, acetic acid and acetate.

The present invention provides two specific embodiments in which the pharmaceutical composition contains the following components by weight or consists of the following components:

Temozolomide or its salt in terms of temozolomide

10 parts of vitamin C

Polysorbate 80 3 parts

Mannitol 6 parts

In addition, the present invention also provides a method of preparing a pharmaceutical composition. The preparation method comprises the step of uniformly mixing temozolomide or a pharmaceutically acceptable salt thereof with at least one vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof.

Specifically, the preparation method of the present invention comprises the following steps:

1) at least one vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof is dissolved in an aqueous diluent to form a solution, preferably the solution temperature is controlled at 0 to 60 ° C;

2) Temozolomide or a pharmaceutically acceptable salt thereof is added to the above solution to dissolve.

The above preparation method specifically includes the following steps:

1) weighing a prescribed amount of vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof, and optionally a wetting agent, excipient or buffer, and stirring and dissolving in an aqueous diluent;

2) Weighing a prescribed amount of temozolomide or a pharmaceutically acceptable salt thereof, stirring and dissolving in the above solution, and adjusting the pH of the solution using a pH adjuster; preferably, the pH is 2.0 to 6.0, more preferably 2.5 to 5, most Preferably 3 to 4.5;

3) Add the aqueous diluent to the final volume and mix well.

The aqueous diluent used in the above preparation method is selected from the group consisting of water, physiological saline, 5% dextrose solution or a mixture thereof.

The pharmaceutical composition of the present invention can be further prepared into a lyophilized powder preparation, and a mixed solution of temozolomide or a pharmaceutically acceptable salt thereof and vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof can be freeze-dried.

The inventors have found in the study that the addition of vitamin C to the temozolomide composition has the effect of increasing the solubility of temozolomide in the case of ensuring the stability of the finally prepared temozolomide lyophilized powder, which is unexpected to those skilled in the art. .

In another embodiment of the invention, the pharmaceutical composition further comprises at least one wetting agent. The wetting agent is selected from the group consisting of polysorbate, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, bile salt, lecithin, polyethylene glycol or a mixture thereof, preferably polysorbate, most Preferred is polysorbate-80.

In another embodiment of the invention, the pharmaceutical composition further comprises at least one buffer. The buffering agent is selected from the group consisting of citrate, lactate, acetate, tartrate, succinate, phosphate or mixtures thereof, preferably selected from the group consisting of citrate, acetate, phosphate or mixtures thereof, most Preferred is acetate or citrate.

In another embodiment of the invention, the pharmaceutical composition further comprises at least one pH adjusting agent. The pH adjusting agent is selected from the group consisting of hydrochloric acid, sodium hydroxide, citric acid, phosphoric acid, lactic acid, tartaric acid, succinic acid or a mixture thereof, preferably hydrochloric acid or acetic acid. The present invention is prepared as a solution preparation, and particularly when the preparation is injected, the pH of the solution is from 2.0 to 6.0, more preferably from 2.5 to 5, most preferably from 3 to 4.5.

The term "percent by weight" (wt%) used in the present invention is calculated on the basis of the total weight of the pharmaceutical composition.

The present invention can increase the dissolution rate and solubility of temozolomide by the addition of vitamin C and/or its derivative, thereby enabling the volume of the solution to be reduced before lyophilization.

The invention improves the temozolomide which is difficult to be wetted by water due to the poor water solubility by the addition of the wetting agent, increases the dissolution rate of temozolomide, reduces the preparation time of the whole solution, and reduces the degradation time of temozolomide in the solution. Thereby reducing the degradation of temozolomide.

When the pharmaceutical composition of the present invention is prepared into a lyophilized preparation, the final formability of the temozolomide lyophilized powder injection is ensured by the addition of the excipient, and the protective support of the excipient is provided to make the temozolomide freeze-dried powder injection. The time to reconstitute a formulation suitable for administration to a patient is greatly reduced. When the excipient is used in a pharmaceutical formulation, it may be in a pharmaceutical formulation at a wt% of the total weight of the formulation of from 5 wt% to 80 wt%. The addition of a buffering agent and a conventional pH adjusting agent in the present invention ensures that temozolomide reduces its degradation rate in a relatively low pH environment and a certain buffer system in a solution state. When the buffering agent is used in a pharmaceutical formulation, it may be in a pharmaceutical formulation at a wt% of the total weight of the formulation of from 5 wt% to 60 wt%. When a conventional pH adjusting agent is used in a pharmaceutical preparation, its wt% in the pharmaceutical preparation in terms of the total weight of the preparation may be from 0.1% by weight to 20% by weight.

The invention reduces the degradation rate of temozolomide, especially the degradation rate in the dissolution process and the solution state, thereby ensuring that temozolomide can be kept stable in a solution state for a long time, thereby facilitating the preparation of temozolomide into various preparations, and industrialization is easy. Production.

In the preparation method, the temperature should be appropriately adjusted during the preparation of the chemical solution to reduce the degradation of temozolomide.

In order to clarify the invention, a formulation form of the lyophilized preparation is described as an example for comparison.

The pharmaceutical preparation of the present invention is usually obtained by the following steps:

1. Weigh a prescribed amount of vitamin C and / or its derivatives, wetting agent, excipients, buffer, stir and dissolve in at least one aqueous diluent, the aqueous diluent is about 90% of the prescription amount, water temperature Regulated at 0 to 60 °C.

2. Weigh the prescribed amount of temozolomide, stir and dissolve in the above solution, and completely dissolve the solution to determine the pH value of the solution. If necessary, adjust the pH of the solution using a conventional pH adjuster.

3. Add the aqueous diluent to the final volume and continue stirring the solution until it is well mixed.

4. The above solution was sterilized by filtration and lyophilized.

Example 1

Weigh 2.50 g of vitamin C, 2.50 g of mannitol, 2.35 g of sodium citrate, 0.80 g of hydrochloric acid, add 900 mL of water for injection, stir and dissolve in a water bath at 40 ° C, and add 2.50 g of temozolomide (Jiangsu Hengrui Pharmaceutical Co., Ltd., below) In the examples, the sources were the same), stirred and dissolved, water was added to 1000 mL, filtered through a 0.22 μm microporous membrane, and divided, and lyophilized to obtain a temozolomide lyophilized powder.

Example 2

Weigh 3.00 g of polysorbate-80, 2.50 g of vitamin C, 2.50 g of mannitol, 2.35 g of sodium citrate, 0.80 g of hydrochloric acid, add 900 mL of water for injection, stir to dissolve in a water bath at 40 ° C, and add 2.50 g of temozolomide. Stir and dissolve, add water to 1000 mL, filter with 0.22 μm microporous membrane, dispense and freeze-dry to obtain temozolomide lyophilized powder.

Example 3

Weigh 3.00 g of polysorbate-80, 10.00 g of vitamin C, 6.00 g of mannitol, 2.35 g of sodium citrate, add 900 mL of water for injection which has been cooled to room temperature, stir to dissolve, and adjust the pH of the solution to 4.0 with hydrochloric acid. Add 5.00 g of temozolomide, stir to dissolve, add water to 1000 mL, filter with 0.22 μm microporous membrane, dispense and freeze-dry to obtain temozolomide lyophilized powder.

Example 4

Weigh 3.00g polysorbate-80, 25.00g vitamin C, 6.00g mannitol, 2.35g sodium citrate, add 900mL of water for injection cooled to room temperature, stir to dissolve, adjust the pH of the solution to 4.0 with hydrochloric acid. Add 5.00 g of temozolomide, stir to dissolve, add water to 1000 mL, filter with 0.22 μm microporous membrane, dispense and freeze-dry to obtain temozolomide lyophilized powder.

Example 5

Weigh 3.00 g of polysorbate-80, 50.00 g of vitamin C, 6.00 g of mannitol, 2.35 g of sodium citrate, add 900 mL of water for injection which has been cooled to room temperature, stir to dissolve, and adjust the pH of the solution to 4.0 with hydrochloric acid. 10.00 g of temozolomide was added, dissolved by stirring, water was added to 1000 mL, filtered through a 0.22 μm microporous membrane, and the mixture was lyophilized to obtain a temozolomide lyophilized powder.

Example 6

Weigh 3.00 g of polysorbate-80, 10.00 g of vitamin C, 15.00 g of mannitol, 5.88 g of sodium citrate, add 900 mL of water for injection which has been cooled to room temperature, stir to dissolve, and adjust the pH of the solution to 3.7 with hydrochloric acid. 5.00 g of temozolomide was added, dissolved by stirring, water was added to 1000 mL, filtered through a 0.22 μm microporous membrane, and the mixture was lyophilized to obtain a temozolomide lyophilized powder.

Example 7

Weigh 3.00 g of polysorbate-80, 25.00 g of vitamin C, 15.00 g of mannitol, 5.88 g of sodium citrate, add 900 mL of water for injection which has been cooled to room temperature, stir to dissolve, and adjust the pH of the solution to 3.7 with hydrochloric acid. 5.00 g of temozolomide was added, dissolved by stirring, water was added to 1000 mL, filtered through a 0.22 μm microporous membrane, and the mixture was lyophilized to obtain a temozolomide lyophilized powder.

Comparative Example 1 (conventional freeze-drying prescription)

Weigh 15.00 g of mannitol, 5.88 g of sodium citrate, add 900 mL of water for injection cooled to room temperature, stir to dissolve, adjust the pH of the solution to 3.7 with hydrochloric acid, add 2.50 g of temozolomide, stir to dissolve, add water to 1000 mL, use 0.22 The μm microporous membrane was filtered and lyophilized to obtain a temozolomide lyophilized powder.

Comparative Example 2

Weigh 15.00 g of mannitol, 3.00 g of polysorbate 80, 5.88 g of sodium citrate, add 900 mL of water for injection cooled to room temperature, stir to dissolve, adjust the pH of the solution to 3.7 with hydrochloric acid, add 2.50 g of temozolomide, stir After dissolving, water was added to 1000 mL, filtered through a 0.22 μm microporous membrane, and lyophilized to obtain a temozolomide lyophilized powder.

Comparative Example 3 (U.S. Patent No. 6,987,108, Example 2)

Weigh 15.00 g of mannitol, 3.00 g of polysorbate 80, 4.00 g of L-threonine, 5.88 g of sodium citrate, add 900 mL of water for injection which has been cooled to room temperature, stir to dissolve, and adjust the pH of the solution to 3.7 with hydrochloric acid. 2.50 g of temozolomide was added, dissolved by stirring, water was added to 1000 mL, filtered through a 0.22 μm microporous membrane, and lyophilized to obtain a temozolomide lyophilized powder.

Solubility comparison test

A solution of 5.0 mg/mL of temozolomide was prepared according to Example 6, 7 to obtain a clear clear solution, and the prescribed amount of temozolomide bulk drug could be completely dissolved.

According to the control examples 1, 2, 3, the other excipients were unchanged, and the amount of temozolomide was increased to 5.00 g (concentration: 5.0 mg/mL), and the corresponding solution of temozolomide was prepared. As a result, temozolomide could not be completely dissolved in the corresponding solution, and there were a large amount. Undissolved drug precipitates at the bottom of the solution.

The above comparative test results indicate that vitamin C has a remarkable ability to increase the solubility of temozolomide, and it has been found that even if the amount of L-threonine in Comparative Example 3 is increased, the effect on the solubility of the drug is limited.

Long-term stability experiment

A solution of temozolomide was prepared according to the formulation of Example 3, and the prepared solution was freeze-dried to prepare a temozolomide freeze-dried powder injection. The prepared temozolomide lyophilized powder injection was sampled at 2 to 8 ° C for investigation.

It can be seen from the results in Table 1 that the lyophilized powder prepared in Example 3 has good stability, and there is no change in the related substances for 2 months, indicating that the prepared temozolomide lyophilized powder is stable.

It can be seen from the above two experiments that vitamin C can increase the solubility of temozolomide under the premise of ensuring the stability of the obtained lyophilized powder, which is of great significance for the preparation of temozolomide preparation.

Claims (24)

A pharmaceutical composition comprising temozolomide or a pharmaceutically acceptable salt thereof, and at least one vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof. The pharmaceutical composition according to claim 1, wherein the at least one vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof is vitamin C. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises at least one aqueous diluent. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is an injectable parenteral pharmaceutical preparation. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is in the form of a lyophilized powder. The pharmaceutical composition according to any one of claims 1 to 3, wherein temozolomide or a pharmaceutically acceptable salt thereof, based on temozolomide, vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof The weight ratio of vitamin C to temozolomide is from 0.5 to 10:1 in terms of vitamin C. The pharmaceutical composition according to claim 6, wherein the weight ratio of the vitamin C to temozolomide is from 1 to 5:1. The pharmaceutical composition according to claim 7, wherein the weight ratio of the vitamin C to temozolomide is 2:1. The pharmaceutical composition according to any one of claims 1 to 4, wherein the content of vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof is 10% by weight to 80% by weight based on the total weight of the pharmaceutical composition. %. The pharmaceutical composition according to claim 9, wherein the content of vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof is from 25 to 65 wt% based on the total weight of the pharmaceutical composition. The pharmaceutical composition according to any one of claims 1 to 4, wherein the temozolomide or a pharmaceutically acceptable salt thereof is contained in an amount of 5 wt% to 60 wt% based on the total weight of the pharmaceutical composition. The pharmaceutical composition according to claim 11, wherein the temozolomide or a pharmaceutically acceptable salt thereof is contained in an amount of 10% by weight to 30% by weight based on the total mass of the pharmaceutical composition. The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition comprises one or more of an excipient, a wetting agent, a pH adjuster or a buffer. The pharmaceutical composition according to claim 13, wherein the excipient is mannitol; the wetting agent is polysorbate-80; the pH adjuster is hydrochloric acid; and the buffer is tannic acid. sodium. The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutical composition contains the following components by weight, or consists of the following components: temozolomide in terms of temozolomide or Salt 5 parts Vitamin C 10 parts Polysorbate-80 3 parts Mannitol 6 parts. A method of preparing a pharmaceutical composition according to any one of claims 1 to 15, which comprises temozolomide or a pharmaceutically acceptable salt thereof and at least one vitamin C or a derivative thereof or a pharmaceutically acceptable thereof The step of mixing the salts evenly. The method of claim 16, comprising the steps of: 1) dissolving at least one vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof in an aqueous diluent to form a solution; 2) temozolomide or A pharmaceutically acceptable salt thereof is dissolved in the above solution. The method of claim 17, wherein the solution is temperature controlled at 0 to 60 °C. The method of claim 17, comprising the steps of: 1) weighing a prescribed amount of vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof, and optionally a wetting agent, an excipient Or a buffer, stir and dissolve in the aqueous diluent; 2) weigh the prescribed amount of temozolomide or its pharmaceutically acceptable salt, stir and dissolve in the above solution, adjust the pH of the solution with a pH adjuster; 3) add aqueous dilution Stir to the final volume and mix well. The method of claim 19, wherein the pH is from 2.0 to 6.0. The method of claim 20, wherein the pH is from 2.5 to 5. The method of claim 21, wherein the pH is from 3 to 4.5. The method of claim 17 or 19, wherein the aqueous diluent is selected from the group consisting of water, physiological saline, 5% dextrose solution, or a mixture thereof. The method of claim 17 or 19, further comprising freeze-drying a mixed solution of temozolomide or a pharmaceutically acceptable salt thereof and vitamin C or a derivative thereof or a pharmaceutically acceptable salt thereof to obtain a The step of lyophilizing the powder.